CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 25 of 232 entries

View as:

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

Phase: N/A Priority: Normal

NCT ID: NCT03061331 Org: User:

Start: 01/31/17 End: 10/04/17 Due: 10/04/18

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Phase: N/A Priority: Normal

NCT ID: NCT05329649 Org: User:

Start: 05/02/22 End: 05/31/26 Due: 05/31/27

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Phase: N/A Priority: Normal

NCT ID: NCT04537793 Org: User:

Start: 11/19/20 End: 06/03/22 Due: 06/03/23

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

Phase: N/A Priority: Normal

NCT ID: NCT02971839 Org: User:

Start: 12/31/16 End: 08/31/17 Due: 08/31/18

Study of Telaprevir in Subjects With Hepatic Impairment

Phase: N/A Priority: Normal

NCT ID: NCT00509210 Org: User:

Start: 09/30/07 End: 06/30/08 Due: 06/30/09

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

Phase: N/A Priority: Normal

NCT ID: NCT00909727 Org: User:

Start: 08/31/09 End: 04/30/11 Due: 04/30/12

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

Phase: N/A Priority: Normal

NCT ID: NCT05324410 Org: User:

Start: 04/07/22 End: 11/07/22 Due: 11/07/23

A Long-term Follow-up Study in Participants Who Received CTX001

Phase: N/A Priority: Normal

NCT ID: NCT04208529 Org: User:

Start: 01/20/21 End: 09/30/39 Due: 09/30/40

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Phase: N/A Priority: Normal

NCT ID: NCT05444257 Org: User:

Start: 11/08/22 End: 10/31/26 Due: 10/31/27

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Phase: N/A Priority: Normal

NCT ID: NCT05704556 Org: User:

Start: 02/27/23 End: 03/30/24 Due: 03/30/25

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Phase: N/A Priority: Normal

NCT ID: NCT03911713 Org: User:

Start: 04/17/19 End: 08/20/20 Due: 08/20/21

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

Phase: N/A Priority: Normal

NCT ID: NCT06394167 Org: User:

Start: 05/09/24 End: 02/18/25 Due: 02/18/26

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Phase: N/A Priority: Normal

NCT ID: NCT06336096 Org: User:

Start: 03/28/24 End: 06/19/24 Due: 06/19/25

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Phase: N/A Priority: Normal

NCT ID: NCT01726946 Org: User:

Start: 11/30/12 End: 02/28/14 Due: 02/28/15

VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00003847 Org: User:

Start: 12/31/98 End: - Due: -

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

Phase: N/A Priority: Normal

NCT ID: NCT00865904 Org: User:

Start: 03/31/09 End: 12/31/09 Due: 12/31/10

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT00966602 Org: User:

Start: 09/30/09 End: 12/31/09 Due: 12/31/10

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Phase: N/A Priority: Normal

NCT ID: NCT03691779 Org: User:

Start: 10/02/18 End: 08/07/20 Due: 08/07/21

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Phase: N/A Priority: Normal

NCT ID: NCT01459913 Org: User:

Start: 11/30/11 End: 01/31/14 Due: 01/31/15

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Phase: N/A Priority: Normal

NCT ID: NCT03559062 Org: User:

Start: 05/17/18 End: 12/21/18 Due: 12/21/19

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

Phase: N/A Priority: Normal

NCT ID: NCT06176196 Org: User:

Start: 12/13/23 End: 10/16/24 Due: 10/16/25

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Phase: N/A Priority: Normal

NCT ID: NCT03068312 Org: User:

Start: 07/18/17 End: 12/18/18 Due: 12/18/19

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

Phase: N/A Priority: Normal

NCT ID: NCT02660424 Org: User:

Start: 12/31/15 End: 09/30/16 Due: 09/30/17

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Phase: N/A Priority: Normal

NCT ID: NCT03655678 Org: User:

Start: 09/14/18 End: 12/08/25 Due: 12/08/26

A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal

NCT ID: NCT01052194 Org: User:

Start: 02/28/10 End: 07/31/11 Due: 07/31/12

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation	NCT03061331	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2017-01-31	2017-10-04	2018-10-04	-	-	2025-07-14
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)	NCT05329649	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2022-05-02	2026-05-31	2027-05-31	-	-	2025-07-14
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years	NCT04537793	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2020-11-19	2022-06-03	2023-06-03	-	-	2025-07-14
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations	NCT02971839	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2016-12-31	2017-08-31	2018-08-31	-	-	2025-07-14
Study of Telaprevir in Subjects With Hepatic Impairment	NCT00509210	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2007-09-30	2008-06-30	2009-06-30	-	-	2025-07-14
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation	NCT00909727	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2009-08-31	2011-04-30	2012-04-30	-	-	2025-07-14
A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants	NCT05324410	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2022-04-07	2022-11-07	2023-11-07	-	-	2025-07-14
A Long-term Follow-up Study in Participants Who Received CTX001	NCT04208529	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2021-01-20	2039-09-30	2040-09-30	-	-	2025-07-14
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy	NCT05444257	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2022-11-08	2026-10-31	2027-10-31	-	-	2025-07-14
Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment	NCT05704556	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2023-02-27	2024-03-30	2025-03-30	-	-	2025-07-14
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis	NCT03911713	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2019-04-17	2020-08-20	2021-08-20	-	-	2025-07-14
A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults	NCT06394167	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2024-05-09	2025-02-18	2026-02-18	-	-	2025-07-14
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine	NCT06336096	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2024-03-28	2024-06-19	2025-06-19	-	-	2025-07-14
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C	NCT01726946	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2012-11-30	2014-02-28	2015-02-28	-	-	2025-07-14
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer	NCT00003847	Vertex Pharmaceuticals Incorporated	user2@example.com	None	1998-12-31	-	-	-	-	2025-07-14
Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation	NCT00865904	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2009-03-31	2009-12-31	2010-12-31	-	-	2025-07-14
Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects	NCT00966602	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2009-09-30	2009-12-31	2010-12-31	-	-	2025-07-14
Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age	NCT03691779	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2018-10-02	2020-08-07	2021-08-07	-	-	2025-07-14
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype	NCT01459913	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2011-11-30	2014-01-31	2015-01-31	-	-	2025-07-14
A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis	NCT03559062	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2018-05-17	2018-12-21	2019-12-21	-	-	2025-07-14
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)	NCT06176196	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2023-12-13	2024-10-16	2025-10-16	-	-	2025-07-14
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation	NCT03068312	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2017-07-18	2018-12-18	2019-12-18	-	-	2025-07-14
A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee	NCT02660424	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2015-12-31	2016-09-30	2017-09-30	-	-	2025-07-14
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia	NCT03655678	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2018-09-14	2025-12-08	2026-12-08	-	-	2025-07-14
A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis	NCT01052194	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2010-02-28	2011-07-31	2012-07-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance